Esophageal cancer remains a significant global health challenge, requiring a deeper understanding of its complex metabolic underpinnings. Recent research has highlighted esophageal cancer lactylation as a critical driver of malignancy and metabolic shift. Specifically, the study focuses on how the protein DCBLD1 undergoes a post-translational modification called lactylation, which subsequently stabilizes PDIA3 to reprogram cellular metabolism.

Metabolic reprogramming is a well-known hallmark of cancer. Tumor cells often rely on aerobic glycolysis, a process that generates high levels of lactate even in the presence of oxygen. While scientists once considered lactate a metabolic waste product, they now recognize it as a key signaling molecule. In esophageal cancer, elevated lactate levels promote the lactylation of DCBLD1, significantly enhancing its stability and oncogenic function.

Mechanistic Insights into Esophageal Cancer Lactylation

The research established that DCBLD1 acts as a potent carcinogenic gene in this context. When DCBLD1 undergoes lysine lactylation (Kla), its half-life increases. This stabilization is particularly evident when tumor cells encounter high lactate concentrations. Conversely, inhibitors such as 2-deoxy-d-glucose (2-DG) can shorten the protein's half-life by reducing the available lactate for modification.

Furthermore, the stabilized DCBLD1 interacts directly with PDIA3, a member of the protein disulfide isomerase family. This interaction effectively prevents the degradation of PDIA3. The resulting accumulation of PDIA3 facilitates a metabolic shift toward increased glycolysis, fueling the rapid proliferation and migration of cancer cells. Consequently, this pathway promotes tumor progression and inhibits apoptosis both in vitro and in vivo.

Therapeutic Potential of Targeting the LDHA-DCBLD1 Axis

The study also underscored the vital role of lactate dehydrogenase A (LDHA), the enzyme responsible for lactate production. Researchers found that interfering with LDHA decreased the levels of both DCBLD1 and its lactylated form. Therefore, the LDHA-DCBLD1-PDIA3 axis represents a promising target for therapeutic intervention. By inhibiting this pathway, clinicians may eventually be able to suppress tumor progression and reverse metabolic reprogramming in patients with esophageal malignancies.

Frequently Asked Questions

What is the clinical significance of DCBLD1 in esophageal cancer?

DCBLD1 is highly expressed in esophageal cancer tissues and serves as an oncogene. Its stabilization through lactylation promotes tumor growth and metastasis, making it a potential biomarker for prognosis and a high-value target for future therapy.

How does lactate influence the stability of PDIA3?

Lactate induces the lactylation of DCBLD1. Once lactylated, DCBLD1 binds to and stabilizes PDIA3, preventing its degradation. This allows PDIA3 to support the glycolytic metabolism necessary for rapid cancer cell survival and growth.

Can inhibiting glycolysis help treat esophageal cancer?

Yes, research shows that inhibiting glycolysis or reducing lactate production (via LDHA interference) can decrease the oncogenic activity of the DCBLD1-PDIA3 complex, thereby slowing tumor progression and sensitizing cells to apoptosis.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a substitute for professional healthcare. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Yin M et al. Lactylation-augmented DCBLD1-mediated PDIA3 stabilization reprograms glycolysis metabolism in oesophageal cancer. J Cancer Res Clin Oncol. 2026 May 31. doi: 10.1007/s00432-026-06517-6. PMID: 42218727.

2. Zhang D et al. Metabolic regulation of gene expression by histone lysine lactylation. Nature. 2019;574(7779):575-580. doi: 10.1038/s41586-019-1678-1.

3. Gao F et al. Lactate and lactylation: metabolic architects of tumor progression and metastasis. Signal Transduct Target Ther. 2024. doi: 10.1038/s41392-024-00123-x.